MX347291B - Inmunoglobulinas portadoras y usos de las mismas. - Google Patents

Inmunoglobulinas portadoras y usos de las mismas.

Info

Publication number
MX347291B
MX347291B MX2014010300A MX2014010300A MX347291B MX 347291 B MX347291 B MX 347291B MX 2014010300 A MX2014010300 A MX 2014010300A MX 2014010300 A MX2014010300 A MX 2014010300A MX 347291 B MX347291 B MX 347291B
Authority
MX
Mexico
Prior art keywords
antigen binding
binding protein
disclosed
pharmacologically active
antibody
Prior art date
Application number
MX2014010300A
Other languages
English (en)
Inventor
C Boone Thomas
W Walker Kenneth
DOELLGAST George (FINADO)
Li Yue-Sheng
Min Hosung
Talvenheimo Jane
Arora Taruna
W Jacobsen Frederick
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX347291B publication Critical patent/MX347291B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/66—Thymopoietins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se refiere a una proteína de unión al antígeno aislada, tal como pero a modo no taxativo, un anticuerpo o fragmento de anticuerpo. También se describen composiciones farmacéuticas y medicamentos que comprenden la proteína de unión al antígeno, ácido nucleico aislado que la codifica, vectores,células hospedadoras e hibridomas útiles para los métodos de su realización. En algunas modalidades, la proteína de unión al antígeno comprende de uno a veinticuatro restos químicos farmacológicamente activos conjugados a la misma, tal como un polipéptido farmacológicamente activo.
MX2014010300A 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas. MX347291B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21059409P 2009-03-20 2009-03-20
PCT/US2010/028060 WO2010108153A2 (en) 2009-03-20 2010-03-19 Carrier immunoglobulins and uses thereof

Publications (1)

Publication Number Publication Date
MX347291B true MX347291B (es) 2017-04-17

Family

ID=42740266

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2011009797A MX2011009797A (es) 2009-03-20 2010-03-19 Inhibidores peptidicos de kv1.3 potentes selectivos.
MX2014010300A MX347291B (es) 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas.
MX2014010302A MX347295B (es) 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas.
MX2011009798A MX2011009798A (es) 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011009797A MX2011009797A (es) 2009-03-20 2010-03-19 Inhibidores peptidicos de kv1.3 potentes selectivos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014010302A MX347295B (es) 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas.
MX2011009798A MX2011009798A (es) 2009-03-20 2010-03-19 Inmunoglobulinas portadoras y usos de las mismas.

Country Status (7)

Country Link
US (5) US20120121591A1 (es)
EP (3) EP3385279B1 (es)
JP (5) JP2012521360A (es)
AU (2) AU2010226392B9 (es)
CA (4) CA2755133A1 (es)
MX (4) MX2011009797A (es)
WO (2) WO2010108153A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
BR112013023674A2 (pt) 2011-03-16 2016-12-13 Amgen Inc inibidores potentes e seletivos de nav1.3 e nav1.7
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2717899A4 (en) * 2011-06-06 2015-07-29 Kineta One Llc PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS OF MAKING AND USING THE SAME
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
AR086866A1 (es) 2011-06-10 2014-01-29 Hanmi Science Co Ltd Derivados de oxintomodulina y composicion farmaceutica que los comprende para el tratamiento de la obesidad
PT2721062T (pt) 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
WO2013184514A1 (en) * 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102311517B1 (ko) 2012-11-06 2021-10-14 한미약품 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
PT2948559T (pt) * 2013-01-25 2018-07-24 Janssen Biotech Inc ¿antagonistas de kv1.3 e métodos de utilização
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
AR096927A1 (es) 2013-03-12 2016-02-10 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US9708377B2 (en) 2013-10-28 2017-07-18 Monash University Scorpion toxin analogue and method for treating autoimmune diseases
SG11201605093VA (en) * 2013-12-23 2016-07-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
CN106661128A (zh) * 2014-06-06 2017-05-10 加州生物医学研究所 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
US9710451B2 (en) * 2014-06-30 2017-07-18 International Business Machines Corporation Natural-language processing based on DNA computing
US10246496B2 (en) 2014-08-15 2019-04-02 La Trobe University Potassium channel blockers and use thereof in the treatment of autoimmune diseases
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
JP6913030B2 (ja) 2015-05-18 2021-08-04 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
EP3313526B1 (en) 2015-06-29 2023-11-08 The University Of British Columbia B1sp fusion protein therapeutics, methods, and uses
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
US10388404B2 (en) 2015-10-27 2019-08-20 International Business Machines Corporation Using machine-learning to perform linear regression on a DNA-computing platform
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
EP4011919A3 (en) 2015-12-09 2022-10-12 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CA3010224A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
WO2018013483A1 (en) * 2016-07-11 2018-01-18 The California Institute For Biomedical Research Kv1.3 channel blocking peptides and uses thereof
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
CA3070209A1 (en) * 2017-01-19 2018-07-26 The University Of Tokyo Novel fluorescent labeling method
US11208477B2 (en) 2019-04-01 2021-12-28 Novo Nordisk A/S Antibodies and use thereof
BR112022010680A2 (pt) 2019-12-03 2022-08-16 Evotec Int Gmbh Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
JP7458085B2 (ja) * 2021-07-28 2024-03-29 株式会社三協 錠剤用崩壊剤及びこれを利用した錠剤
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
US20250188163A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
US20250276080A1 (en) 2024-02-29 2025-09-04 Amgen Inc. Glucagon receptor agonists and conjugates to glucose-dependent insulinotropic polypeptide antagonists
CN120795162A (zh) 2024-04-02 2025-10-17 康诺亚生物医药科技（成都）有限公司 针对il-13和tslp的双特异性抗体及其用途
WO2025244108A1 (ja) * 2024-05-23 2025-11-27 国立大学法人 東京大学 新規蛍光標識方法
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE68925893T2 (de) 1988-07-23 1996-08-08 Delta Biotechnology Ltd Sekretorische leader-sequenzen
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
FI92507C (fi) 1991-12-19 1994-11-25 Valto Ilomaeki Menetelmä ja laite maaperään pakotettavien putkien ohjaamiseksi
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
CA2184002A1 (en) 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
AU5369798A (en) * 1996-11-27 1998-06-22 Bachem Bioscience, Inc. Shk toxin compositions and methods of use
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ATE307829T1 (de) 1996-12-26 2005-11-15 Suntory Ltd Skorpion-spezifische neuropeptide
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7029909B1 (en) 1998-11-20 2006-04-18 Fuso Pharmaceutical Industries, Ltd. Protein expression vector and utilization thereof
JP2002538841A (ja) 1999-03-18 2002-11-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
HUP0204142A3 (en) 2000-02-25 2004-12-28 Univ Durham Anti-egfrviii scfv-antibodies with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
EP2845864A3 (en) 2001-05-11 2015-06-10 Amgen, Inc Peptides and related molecules that bind to TALL - 1
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2826735C (en) 2003-04-30 2019-06-04 University Of Zurich Methods for treating cancer using an immunotoxin
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
EP1709080B1 (en) 2004-01-09 2011-03-09 Pfizer Inc. ANTIBODIES TO MAdCAM
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
EP2474316B1 (en) * 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
MX2007005865A (es) 2004-11-16 2008-02-25 Amben Mountain View Inc Adamios de proteina y usos de los mismos.
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
KR101017301B1 (ko) 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2007009069A2 (en) 2005-07-13 2007-01-18 Amgen Mountain View Inc. Heat lysis production of proteins
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8043829B2 (en) 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
DK3564674T3 (da) 2006-11-01 2021-10-18 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
IN2009DN05758A (es) 2007-03-12 2015-07-24 Esbatech Ag
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2009086411A2 (en) 2007-12-27 2009-07-09 Abbott Laboratories Negative mimic antibody for use as a blocking reagent in bnp immunoassays
JP2011515376A (ja) 2008-03-20 2011-05-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 病的血栓形成に必須であるカルシウムセンサＳＴＩＭ１及び血小板ＳＯＣチャネルＯｒａｉ１（ＣＲＡＣＭ１）
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
EP2528948B1 (en) 2010-01-28 2018-09-19 AB Biosciences, Inc. Novel lowered affinity antibodies and methods of making the same
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof

Also Published As

Publication number Publication date
WO2010108154A2 (en) 2010-09-23
US20120195879A1 (en) 2012-08-02
US20120121591A1 (en) 2012-05-17
JP2015120706A (ja) 2015-07-02
US8734796B2 (en) 2014-05-27
US9562108B2 (en) 2017-02-07
EP3385279B1 (en) 2020-02-26
EP2408814A4 (en) 2013-01-09
CA2755133A1 (en) 2010-09-23
EP3385279A1 (en) 2018-10-10
MX347295B (es) 2017-04-20
AU2010226391B2 (en) 2013-11-14
CA2889453C (en) 2018-11-06
CA3018235A1 (en) 2010-09-23
US20150044236A1 (en) 2015-02-12
US10189912B2 (en) 2019-01-29
CA2755336A1 (en) 2010-09-23
JP6609347B2 (ja) 2019-11-20
JP2018139609A (ja) 2018-09-13
US20150044235A1 (en) 2015-02-12
CA2889453A1 (en) 2010-09-23
JP2017163986A (ja) 2017-09-21
JP6345832B2 (ja) 2018-06-20
EP2408814B1 (en) 2018-11-21
WO2010108153A2 (en) 2010-09-23
AU2010226392B9 (en) 2014-05-22
CA3018235C (en) 2021-01-12
EP2432488A2 (en) 2012-03-28
EP2432488A4 (en) 2014-01-08
CA2755336C (en) 2015-07-14
AU2010226392A1 (en) 2011-10-06
MX2011009798A (es) 2011-12-08
US20170190793A1 (en) 2017-07-06
AU2010226391A1 (en) 2011-10-13
JP2012521197A (ja) 2012-09-13
MX2011009797A (es) 2012-01-12
JP6173359B2 (ja) 2017-08-02
AU2010226392B2 (en) 2014-04-03
JP2012521360A (ja) 2012-09-13
US9562107B2 (en) 2017-02-07
WO2010108154A3 (en) 2011-03-03
AU2010226391C1 (en) 2016-11-24
WO2010108153A3 (en) 2010-11-18
EP2408814A2 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MX2011009798A (es) Inmunoglobulinas portadoras y usos de las mismas.
MX2013003274A (es) Inmunoglobulinas portadoras y usos de las mismas.
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
MX348360B (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
WO2013059885A3 (en) Polypeptide constructs and uses thereof
MX354717B (es) Moleculas de union novedosas con actividad antitumoral.
MX2011003502A (es) Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ597692A (en) Anti-IGF antibodies
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
FR2911608B1 (fr) Nouvelles compositions vaccinales anti paludique et ses utilisations.
EP2098594A4 (en) NUCLEIC ACID MOLECULE WITH ABILITY TO BIND TO RABBIT FROM IGNIOR ANTIBODIES
WO2010127180A3 (en) Dc-stamp antibodies
WO2012177418A8 (en) Nucleic acid molecules encoding enzymes that confer disease resistance in jute
UA99714C2 (ru) Моноклональное антитело, которое специфически связывается с light
WO2005092922A3 (de) Antigen des pm-2 antikörpers und dessen verwendung